John Mendlein - Mar 10, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Director
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Mar 10, 2022
Transactions value $
-$1,053,754
Form type
4
Date filed
3/11/2022, 03:58 PM
Previous filing
Jul 29, 2021
Next filing
Jun 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $51.4K +31.6K +19.79% $1.63 191K Mar 10, 2022 Direct F1
transaction FATE Common Stock Sale -$677K -19.5K -10.2% $34.73 172K Mar 10, 2022 Direct F1, F2
transaction FATE Common Stock Sale -$428K -12.1K -7.04% $35.48 159K Mar 10, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -31.6K -100% $0.00* 0 Mar 10, 2022 Common Stock 31.6K $1.63 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.
F2 Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
F3 Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
F4 This option is fully vested.